FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Ellen Weisberg

Research Profile

Chemicals & Drugs

Physiology

Living Beings

Mouse

Disorders

Phenomena

Phosphorylation

Anatomy

Co-author Network

Publications

TOP 3
Ellen Weisberg; Jianming Zhang; Xin Zhang; Ilene Galinsky; James D Griffin; Feiyang Liu; Qingsong Liu; Constantine Mitsiades; Erik Nelson; Maria Nicolais; Atsushi Nonami; Martin Sattler; Robert W Smith; Richard Stone; Nathanael Gray
Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells.
Ellen Weisberg; Z Zhao; R Bronson; A L Christie; J F Daley; Ilene Galinsky; James D Griffin; W Hur; Andrew L Kung; Q Liu; Constantine S Mitsiades; Erik Nelson; T Sanda; Martin Sattler; R Smith; Richard M Stone; N Gray
Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors.
Erik A Nelson; Maria Nicolais; Richard M Stone; Sarah R Walker; Ellen Weisberg; Michael Xiang; Michal Bar-Natan; Rosemary Barrett; Amanda L Christie; James D Griffin; Surender Kharbanda; Andrew L Kung; Suiyang Liu; David A Frank
The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Ellen Weisberg (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Ellen Weisberg; Jianming Zhang; Xin Zhang; Ilene Galinsky; James D Griffin; Feiyang Liu; Qingsong Liu; Constantine Mitsiades; Erik Nelson; Maria Nicolais; Atsushi Nonami; Martin Sattler; Robert W Smith; Richard Stone; Nathanael Gray
Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells.
PloS one 2013;8(2):e56473.
2012: Ellen Weisberg; Z Zhao; R Bronson; A L Christie; J F Daley; Ilene Galinsky; James D Griffin; W Hur; Andrew L Kung; Q Liu; Constantine S Mitsiades; Erik Nelson; T Sanda; Martin Sattler; R Smith; Richard M Stone; N Gray
Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors.
Leukemia 2012;26(10):2233-44.
2012: Erik A Nelson; Maria Nicolais; Richard M Stone; Sarah R Walker; Ellen Weisberg; Michael Xiang; Michal Bar-Natan; Rosemary Barrett; Amanda L Christie; James D Griffin; Surender Kharbanda; Andrew L Kung; Suiyang Liu; David A Frank
The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations.
Genes & cancer 2012;3(7-8):503-11.
2012: Ellen Weisberg; Andrew L Kung; P W Manley; A K Azab; R Bronson; A L Christie; I M Ghobrial; James D Griffin
Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib.
Leukemia 2012;26(5):985-90.
2011: Erik A Nelson; Sarah R Walker; Ellen Weisberg; Michal Bar-Natan; Rosemary Barrett; Laurie B Gashin; Shariya Terrell; Josephine L Klitgaard; Loredana Santo; Martha R Addorio; Benjamin L Ebert; James D Griffin; David A Frank
The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors.
Blood 2011;117(12):3421-9.
2011: Ellen Weisberg; Chengsheng Zhang; Erik Nelson; Arghya Ray; Martin Sattler; Sophia Adamia; Rosemary Barrett; John F Daley; Edward Fox; David Frank; James D Griffin
Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells.
PloS one 2011;6(9):e25351.
2010: Ellen Weisberg; Arghya Ray; R Barrett; E Nelson; A L Christie; D Porter; C Straub; Leigh Zawel; J F Daley; S Lazo-Kallanian; Richard M Stone; Ilene Galinsky; D Frank; Andrew L Kung; James D Griffin
Smac mimetics: implications for enhancement of targeted therapies in leukemia.
Leukemia 2010;24(12):2100-9.
2010: Ellen Weisberg; Guido Bold; Georgio Caravatti; Andreas Flörsheimer; Pascal Furet; Patricia Imbach; Jingrui Jiang; Paul Manley; Arghya Ray; Johannes Roesel; James D Griffin
Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison.
Genes & cancer 2010;1(10):1021-32.
2010: Ellen Weisberg; M Sattler; Arghya Ray; James D Griffin
Drug resistance in mutant FLT3-positive AML.
Oncogene 2010;29(37):5120-34.
2010: Ellen Weisberg; Hwan Geun Choi; Rosemary Barrett; Wenjun Zhou; Jianming Zhang; Arghya Ray; Erik A Nelson; Jingrui Jiang; Daisy Moreno; Richard Stone; Ilene Galinsky; Edward Fox; Sophia Adamia; Andrew L Kung; Nathanael S Gray; James D Griffin
Discovery and characterization of novel mutant FLT3 kinase inhibitors.
Molecular cancer therapeutics 2010;9(9):2468-77.
2010: Rehan Ahmad; Suiyang Liu; Ellen Weisberg; Erik Nelson; Ilene Galinsky; Colin Meyer; Donald Kufe; Surender Kharbanda; Richard Stone
Combining the FLT3 inhibitor PKC412 and the triterpenoid CDDO-Me synergistically induces apoptosis in acute myeloid leukemia with the internal tandem duplication mutation.
Molecular cancer research : MCR 2010;8(7):986-93.
2010: Ellen Weisberg; X Deng; H G Choi; R Barrett; Sophia Adamia; A Ray; Daisy Moreno; Andrew L Kung; N Gray; James D Griffin
Beneficial effects of combining a type II ATP competitive inhibitor with an allosteric competitive inhibitor of BCR-ABL for the treatment of imatinib-sensitive and imatinib-resistant CML.
Leukemia 2010;24(7):1375-8.
2010: Ellen Weisberg; Hwan Geun Choi; Arghya Ray; Rosemary Barrett; Jianming Zhang; Taebo Sim; Wenjun Zhou; Markus Seeliger; Michael Cameron; Mohammed Azam; Jonathan A Fletcher; Maria Debiec-Rychter; Mark Mayeda; Daisy Moreno; Andrew L Kung; Pasi A Janne; Roya Khosravi-Far; Junia V Melo; Paul W Manley; Sophia Adamia; Catherine Wu; Nathanael Gray; James D Griffin
Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants.
Blood 2010;115(21):4206-16.
2009: Ellen Weisberg; Rosemary Barrett; Qingsong Liu; Richard Stone; Nathanael Gray; James D Griffin
FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2009;12(3):81-9.
2008: Ellen Weisberg; Johannes Roesel; Guido Bold; Pascal Furet; Jingrui Jiang; Jan Cools; Renee D Wright; Erik Nelson; Rosemary Barrett; Arghya Ray; Daisy Moreno; Elizabeth Hall-Meyers; Richard Stone; Ilene Galinsky; Edward A Fox; Gary Gilliland; John F Daley; Suzan Lazo-Kallanian; Andrew L Kung; James D Griffin
Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells.
Blood 2008;112(13):5161-70.
2008: Ellen Weisberg; Renee D Wright; Douglas W McMillin; Constantine S Mitsiades; Arghya Ray; Rosemary Barrett; Sophia Adamia; Richard M Stone; Ilene Galinsky; Andrew L Kung; James D Griffin
Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells.
Molecular cancer therapeutics 2008;7(5):1121-9.
2008: Ellen Weisberg; Lolita Banerji; Renee D Wright; Rosemary Barrett; Arghya Ray; Daisy Moreno; Laurence Catley; Jingrui Jiang; Elizabeth Hall-Meyers; Maira Sauveur-Michel; Richard M Stone; Ilene Galinsky; Edward A Fox; Andrew L Kung; James D Griffin
Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells.
Blood 2008;111(7):3723-34.
2007: Ellen Weisberg; Andrew L Kung; Renee D Wright; Daisy Moreno; Laurence Catley; Arghya Ray; Leigh Zawel; Mary Tran; Jan Cools; Gary Gilliland; Constantine S Mitsiades; Douglas W McMillin; Jingrui Jiang; Elizabeth Hall-Meyers; James D Griffin
Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells.
Molecular cancer therapeutics 2007;6(7):1951-61.
2007: Ellen Weisberg; Paul W Manley; Sandra W Cowan-Jacob; Andreas Hochhaus; James D Griffin
Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia.
Nature reviews. Cancer 2007;7(5):345-56.
2007: Ellen Weisberg; Laurence Catley; Renee D Wright; Daisy Moreno; Lolita Banerji; Arghya Ray; Paul W Manley; Jürgen Mestan; Doriano Fabbro; Jingrui Jiang; Elizabeth Hall-Meyers; Linda Callahan; Jamie L DellaGatta; Andrew L Kung; James D Griffin
Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias.
Blood 2007;109(5):2112-20.
2006: Ellen Weisberg; Renee D Wright; Jingrui Jiang; Arghya Ray; Daisy Moreno; Paul W Manley; Doriano Fabbro; Elizabeth Hall-Meyers; Laurence Catley; klaus podar; Andrew L Kung; James D Griffin
Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity.
Gastroenterology 2006;131(6):1734-42.
2006: Laurence Catley; Ellen Weisberg; Tanyel Kiziltepe; Yu-Tzu Tai; Teru Hideshima; Paola Neri; Pierfrancesco Tassone; Peter Atadja; Dharminder Chauhan; Nikhil C Munshi; Kenneth C Anderson
Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells.
Blood 2006;108(10):3441-9.
2006: Ellen Weisberg; Paul Manley; Jürgen Mestan; Sandra W Cowan-Jacob; Arghya Ray; James D Griffin
AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL.
British journal of cancer 2006;94(12):1765-9.
2006: Nishit K Mukhopadhyay; Ellen Weisberg; David Gilchrist; Raphael Bueno; David J Sugarbaker; Michael T Jaklitsch
Effectiveness of trichostatin A as a potential candidate for anticancer therapy in non-small-cell lung cancer.
The Annals of thoracic surgery 2006;81(3):1034-42.
2005: Ellen Weisberg; Paul W Manley; Werner Breitenstein; Josef Brüggen; Sandra W Cowan-Jacob; Arghya Ray; Brian J P Huntly; Doriano Fabbro; Gabriele Fendrich; Elizabeth Hall-Meyers; Andrew L Kung; Jürgen Mestan; George Q Daley; Linda Callahan; Laurence Catley; Cara Cavazza; Mohammad Azam; Azam Mohammed; Donna Neuberg; Renee D Wright; D Gary Gilliland; James D Griffin
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.
Cancer cell 2005;7(2):129-41.
2004: Ellen Weisberg; Laurence Catley; J Kujawa; Peter Atadja; Stacy W Remiszewski; P Fuerst; C Cavazza; Kenneth C Anderson; James D Griffin
Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo.
Leukemia 2004;18(12):1951-63.
2004: Jingrui Jiang; J Guillermo Paez; Jeffrey C Lee; Ronghai Bo; Richard M Stone; Daniel J DeAngelo; Ilene Galinsky; Brian M Wolpin; Anna Jonasova; Paula Herman; Edward A Fox; Titus Boggon; Michael J Eck; Ellen Weisberg; James D Griffin; D Gary Gilliland; Matthew Meyerson; William R Sellers
Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML.
Blood 2004;104(6):1855-8.
2004: Lizi Wu; Karla Kobayashi; Tao Sun; Ping Gao; Jingxuan Liu; Makoto Nakamura; Ellen Weisberg; Nishit K Mukhopadhyay; James D Griffin
Cloning and functional characterization of the murine mastermind-like 1 (Maml1) gene.
Gene 2004;328():153-65.
2003: Kanoko Sawafuji; Yoshitaka Miyakawa; Ellen Weisberg; James D Griffin; Yasuo Ikeda; Masahiro Kizaki
Aminopeptidase inhibitors inhibit proliferation and induce apoptosis of K562 and STI571-resistant K562 cell lines through the MAPK and GSK-3beta pathways.
Leukemia & lymphoma 2003;44(11):1987-96.
2003: Ellen Weisberg; James D Griffin
Resistance to imatinib (Glivec): update on clinical mechanisms.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2003;6(5):231-8.
2003: Laurence Catley; Ellen Weisberg; Yu-Tzu Tai; Peter Atadja; Stacy W Remiszewski; Teru Hideshima; Nicholas Mitsiades; Reshma Shringarpure; Richard LeBlanc; Dharminder Chauhan; Nikhil C Munshi; Robert Schlossman; Paul Richardson; James Griffin; Kenneth C Anderson
NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma.
Blood 2003;102(7):2615-22.
2003: Jan Cools; Elizabeth H Stover; Christina L Boulton; Jason Gotlib; Robert D Legare; Sonia M Amaral; David P Curley; Nicole Duclos; Rebecca Rowan; Jeffery L Kutok; Benjamin H Lee; Ifor Williams; Steven E Coutre; Richard M Stone; Daniel J DeAngelo; Peter Marynen; Paul W Manley; Thomas Meyer; Doriano Fabbro; Donna Neuberg; Ellen Weisberg; James D Griffin; D Gary Gilliland
PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease.
Cancer cell 2003;3(5):459-69.
2003: Martin Sattler; Blanca Scheijen; Ellen Weisberg; James D Griffin
Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.
Advances in experimental medicine and biology 2003;532():121-40.
2002: Boris Lin; klaus podar; Deepak Gupta; Yu-Tzu Tai; Sigui Li; Edie Weller; Teru Hideshima; Suzanne Lentzsch; Faith Davies; Cheng Li; Ellen Weisberg; Robert Schlossman; Paul G Richardson; James D Griffin; Jeanette Wood; Nikhil C Munshi; Kenneth C Anderson
The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment.
Cancer research 2002;62(17):5019-26.
2002: Ellen Weisberg; Christina L Boulton; Louise M Kelly; Paul Manley; Doriano Fabbro; Thomas Meyer; D Gary Gilliland; James D Griffin
Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.
Cancer cell 2002;1(5):433-43.
2002: Benjamin M F Mow; Joya Chandra; Phyllis A Svingen; Christopher G Hallgren; Ellen Weisberg; Timothy J Kottke; Ven L Narayanan; Mark R Litzow; James D Griffin; Edward A Sausville; Ayalew Tefferi; Scott H Kaufmann
Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro.
Blood 2002;99(2):664-71.
2001: K Okuda; Ellen Weisberg; D Gary Gilliland; James D Griffin
ARG tyrosine kinase activity is inhibited by STI571.
Blood 2001;97(8):2440-8.
2001: Ellen Weisberg; James D Griffin
Mechanisms of resistance imatinib (STI571) in preclinical models and in leukemia patients.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2001;4(1):22-8.
2000: Ellen Weisberg; James D Griffin
Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines.
Blood 2000;95(11):3498-505.
1999: S Bao; M S Chang; Daniel Auclair; Y Sun; Yihan Wang; W K Wong; J Zhang; Y Liu; X Qian; R Sutherland; C Magi-Galluzi; Ellen Weisberg; E Y Cheng; L Hao; H Sasaki; M S Campbell; Stine-Kathrein Kraeft; Massimo Loda; K M Lo; Lan Bo Chen
HRad17, a human homologue of the Schizosaccharomyces pombe checkpoint gene rad17, is overexpressed in colon carcinoma.
Cancer research 1999;59(9):2023-8.